Abstract: An emotion estimating device, an emotion estimating system, and an emotion estimating method capable of estimating an emotion of a subject based on information obtained from daily activities can be provided. An emotion estimating device includes an interface that receives input of walking data of a subject measured by a measurement device and emotion data obtained by quantifying the emotion of the subject, a storage that stores the walking data and the emotion data, and an computer that obtains corresponding data in which a plurality of walking parameters included in the walking data stored in the storage are associated with the emotion data. When the interface newly receives the input of the walking data, the computer estimates the emotion of the subject from the plurality of walking parameters included in the newly received walking data, and outputs information indicating the estimated emotion of the subject.

Abstract: An electromagnetic field band-stop filter includes a plurality of unit structures that have reflection characteristics on an electromagnetic wave of a predetermined frequency. Each of the plurality of unit structures includes: a plurality of electrode parts each of which is disposed along a side of a polygon in a non-contact manner with another electrode part; and a plurality of conductor parts which are provided for the plurality of electrode parts on a one-to-one basis and each of which has at least one bent portion between one end and other end, the one ends of the plurality of conductor parts being connected to the electrode parts on a one-to-one basis and the other ends of the plurality of conductor parts being connected at one point on an inner side of the electrode parts in the individual unit structure.

Abstract: Provided is a pharmaceutical composition for enhancing intracellular ATP, including a compound represented by General Formula (I) wherein R1 represents an unsubstituted or substituted phenyl group, R2 represents a cyano group or a nitro group, R3 represents a hydrogen atom or a hydroxyl group, X represents an oxygen atom or —S(O)n—, n represents an integer of 0 to 2, and Y represents an oxygen atom or a sulfur atom, or a pharmaceutically acceptable salt thereof.

Abstract: To easily measure a voltage to ground of electromagnetic interference waves generated on a cable. A capacitance-to-ground measurement mechanism 10 includes a first electrode 11 and a second electrode 12 positioned at equal altitudes to be opposed to the earth, and a first voltage measurement device 15 to measure a voltage generated in a first resistance 14 connected between the first electrode 11 and the second electrode 12 by an output signal from an oscillation circuit 13. A voltage-to-ground measurement mechanism 30 includes a GND electrode 31 positioned at an altitude equal to that of the first electrode 11 and the second electrode 12 to be opposed to the earth, and a second voltage measurement device 33 to measure a voltage generated in a second resistance 32 connected between the GND electrode 31 and a probe 34 that is brought into contact with a cable core 106 as a measurement target.

Abstract: A measurement individual difference correction system for measuring voltage to ground includes a cable comprising a conductor, a floor panel provided on a floor and comprising a conductor, an oscillation circuit connected between the cable and the floor panel, and configured to output a signal, a voltage-to-ground measurement device comprising an upper electrode and a lower electrode positioned apart from each other, and configured to measure voltage between the upper electrode and the lower electrode, and a computation device in communication with the voltage-to-ground measurement device, in which the computation device calculates combined impedance of electrostatic capacity between the user and the cable, impedance of the user, and electrostatic capacity between the user and the upper electrode, by using voltage of the signal output from the oscillation circuit and the voltage between the upper electrode and the lower electrode measured by the voltage-to-ground measurement device.

Abstract: The present invention relates to a prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome, the agent containing an mPGES-1 inhibitor as an active ingredient.

Abstract: A common-mode voltage measurement apparatus according to an embodiment includes a measurement electrode attached to a conductor capable of being brought into contact with a coated cable, a measurement circuit configured to measure a common-mode voltage generated in the cable, and a compensation circuit connected in series between the measurement electrode and the measurement circuit, the compensation circuit being configured to compensate for a parasitic capacitive component formed between the measurement electrode and the conductor.

Abstract: A device includes a resonant voltage measurement unit 10 configured to input a predetermined frequency signal to a circuit including a fixed capacitance formed between a ground and a lower electrode, a variable capacitance formed between an upper electrode that is disposed above the lower electrode and the ground or between the lower electrode and the upper electrode, and a resonance inductor to measure a resonant voltage that is dependent on a current flowing in the resonance inductor when the variable capacitance is changed to cause the circuit to resonate, a pre-correction voltage-to-ground measurement unit 20 configured to measure a pre-correction voltage-to-ground that is a voltage between a measurement electrode, which is disposed at an equal height to the lower electrode and forms a capacitance-to-ground between the measurement electrode and the ground, and a measurement probe connected to a conductor, and a voltage-to-ground correction unit 30 configured to use the fixed capacitance, the variable capa

Abstract: The present invention provides a therapeutic agent or a prophylactic agent of dementia containing xanthine oxidase inhibitor such as a compound represented in formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: To easily measure a voltage to ground of electromagnetic interference waves generated on a cable. A capacitance-to-ground measurement mechanism 10 includes a first electrode 11 and a second electrode 12 positioned at equal altitudes to be opposed to the earth, and a first voltage measurement device 15 to measure a voltage generated in a first resistance 14 connected between the first electrode 11 and the second electrode 12 by an output signal from an oscillation circuit 13. A voltage-to-ground measurement mechanism 30 includes a GND electrode 31 positioned at an altitude equal to that of the first electrode 11 and the second electrode 12 to be opposed to the earth, and a second voltage measurement device 33 to measure a voltage generated in a second resistance 32 connected between the GND electrode 31 and a probe 34 that is brought into contact with a cable core 106 as a measurement target.

Abstract: A common-mode voltage measurement apparatus according to an embodiment includes a measurement electrode attached to a conductor capable of being brought into contact with a coated cable, a measurement circuit configured to measure a common-mode voltage generated in the cable, and a compensation circuit connected in series between the measurement electrode and the measurement circuit, the compensation circuit being configured to compensate for a parasitic capacitive component formed between the measurement electrode and the conductor.

Abstract: The present invention provides a therapeutic agent or a prophylactic agent of dementia containing xanthine oxidase inhibitor such as a compound represented in formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: An electromagnetic field band-stop filter includes a plurality of unit structures that have reflection characteristics on an electromagnetic wave of a predetermined frequency. Each of the plurality of unit structures includes: a plurality of electrode parts each of which is disposed along a side of a polygon in a non-contact manner with another electrode part; and a plurality of conductor parts which are provided for the plurality of electrode parts on a one-to-one basis and each of which has at least one bent portion between one end and other end, the one ends of the plurality of conductor parts being connected to the electrode parts on a one-to-one basis and the other ends of the plurality of conductor parts being connected at one point on an inner side of the electrode parts in the individual unit structure.

Abstract: A sputtering target which is made of an alumina sintered body having a purity of not less than 99.99% by mass %, a relative density of not less than 98%, and an average grain size of less than 5 ?m or is made of an alumina sintered body having a purity of not less than 99.999% by mass % and a relative density of not less than 98%. A sputtered film having an excellent insulation resistance and an excellent homogeneity can be obtained by using the sputtering target.

Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.

Abstract: An object of the present invention is to provide an organic electroluminescent element containing: a plurality of light emitting units interposed between a pair of an anode and a cathode; and a charge generating unit formed between the light emitting units, wherein a light emitting layer of a light emitting unit located in an N-th order from the anode and a light emitting layer of a light emitting unit located in an (N+1)-th order from the anode each contain an emission dopant to emit light of the same emission color; and a largest maximum emission wavelength in a photoluminescent spectrum of the emission dopant in the light emitting layer of the N-th light emitting unit is shorter than a largest maximum emission wavelength in a photoluminescent spectrum of the emission dopant in the light emitting layer of the (N+1)-th light emitting unit.

Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.

Abstract: An object of the present invention is to provide an organic electroluminescent element containing: a plurality of light emitting units interposed between a pair of a semi-transparent electrode and a reflective electrode; and a charge generating unit formed between the light emitting units, wherein a light emitting layer of a light emitting unit located in an N-th order from the semi-transparent electrode and a light emitting layer of a light emitting unit located in an (N+1)-th order from the semi-transparent electrode each contain an emission dopant emitting light of the same emission color; and a largest maximum emission wavelength ?N(max) in an electroluminescent spectrum of the emission dopant in the light emitting layer of the N-th light emitting unit and a largest maximum emission wavelength ?N+1(max) in an electroluminescent spectrum of the emission dopant in the light emitting layer of the (N+1)-th light emitting unit satisfy the conditional expression (1).

Abstract: An object of the present invention is to provide an organic electroluminescent element containing: a plurality of light emitting units interposed between a pair of an anode and a cathode; and a charge generating unit formed between the light emitting units, wherein a light emitting layer of a light emitting unit located in an N-th order from the anode and a light emitting layer of a light emitting unit located in an (N+1)-th order from the anode each contain an emission dopant to emit light of the same emission color; and a largest maximum emission wavelength in a photoluminescent spectrum of the emission dopant in the light emitting layer of the N-th light emitting unit is shorter than a largest maximum emission wavelength in a photoluminescent spectrum of the emission dopant in the light emitting layer of the (N+1)-th light emitting unit.

Abstract: A sputtering target which is made of a magnesium oxide sintered body having a purity of not less than 99.99% or not less than 99.995% by mass %, a relative density of not less than 98%, and an average grain size of not more than 8 ?m. The average grain size of the sputtering target is preferably not more than 5 ?m, more preferably not more than 2 ?m. A sputtered film having an excellent insulation resistance and an excellent homogeneity can be obtained by using the sputtering target.